Arrowhead begins Phase II trial of ARC-AAT to treat AATD

US-based biopharmaceutical firm Arrowhead has commenced its Phase II clinical trial of ARC-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency (AATD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news